Alnylam Pharmaceuticals (ALNY) Set to Announce Quarterly Earnings on Tuesday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, February 6th.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at $124.50 on Monday. The company has a market capitalization of $12,240.00, a PE ratio of -23.71 and a beta of 2.68. Alnylam Pharmaceuticals has a 52-week low of $39.66 and a 52-week high of $147.63. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83.

A number of analysts recently commented on ALNY shares. Credit Suisse Group lifted their price objective on Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the stock an “outperform” rating in a research report on Friday, November 3rd. Piper Jaffray Companies reiterated an “overweight” rating and set a $14.71 price objective (down previously from $188.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, November 2nd. B. Riley started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, November 1st. They set a “buy” rating and a $240.00 price objective for the company. Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a research report on Friday, December 15th. Finally, FBR & Co started coverage on Alnylam Pharmaceuticals in a research report on Monday, October 30th. They set a “buy” rating and a $150.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $123.93.

In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 73,415 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $130.90, for a total value of $9,610,023.50. Following the sale, the chief executive officer now directly owns 223,125 shares of the company’s stock, valued at approximately $29,207,062.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Michael Mason sold 36,745 shares of the firm’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $131.59, for a total value of $4,835,274.55. Following the completion of the sale, the vice president now directly owns 6,352 shares in the company, valued at $835,859.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 220,409 shares of company stock worth $28,667,017. 4.30% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Alnylam Pharmaceuticals (ALNY) Set to Announce Quarterly Earnings on Tuesday” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.com-unik.info/2018/02/05/alnylam-pharmaceuticals-alny-set-to-announce-quarterly-earnings-on-tuesday.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit